

Special Issue

The Role of Extracellular Vesicles in Pathogenesis and Therapeutic Strategies

Message from the Guest Editor

Extracellular vesicles (EVs) are emerging as a valuable source for novel liquid biomarkers, insight into systemic signaling and theranostic tools. EVs, including exosomes and other membrane-bound packets, are released by all cells under a range of conditions, ranging from homeostatic equilibrium to states of cellular stress.

In states of disease, these EVs, depending on their origin, may adaptively ameliorate the disease state or may contribute to the pathogenesis of the disease. Furthermore, because they are released from intercellular spaces into the circulation, they are being investigated through 'liquid biopsies' for various diseases and biological conditions.

The purpose of this Special Issue is to address specific attributes of EVs as liquid biomarkers for personalized medicine. In providing this overview, this Special Issue will delineate the current foundations and tools for the next steps toward the application of EV in therapeutic strategies for the treatment of a wide range of diseases.

Guest Editor

Dr. Allan Stensballe
Department of Clinical Medicine, Aalborg University, 249 Selma
Lagerløfs Vej, 9260 Gistrup, Denmark

Deadline for manuscript submissions

closed (31 October 2020)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/26488

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).